|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatic progenitor cell activation in liver repair显示文摘The liver possesses an extraordinary ability to regenerate after injury.Hepatocyte-driven liver regeneration is the default pathway in response to mild-to-moderate acute liver damage.When replication of mature hepatocytes is blocked,facultative hepatic progenitor cells(HPCs),also referred to as oval cells(OCs)in rodents,are activated.HPC/OCs have the ability to proliferate clonogenically and differentiate into several lineages including hepatocytes and bile ductal epithelia.This is a conserved liver injury response that has been studied in many species ranging from mammals(rat,mouse,and human)to fish.In addition,improper HPC/OC activation is closely associated with fibrotic responses,characterized by myofibroblast activation and extracellular matrix production,in many chronic liver diseases.Matrix remodeling and metalloprotease activities play an important role in the regulation of HPC/OC proliferation and fibrosis progression.Thus,understanding molecular mechanisms underlying HPC/OC activation has therapeutic implications for rational design of anti-fibrotic therapies. | Adam Bria Jorgensen Marda Junmei Zhou Xiaowei Sun Qi Cao Bryon E.Petersen Liya Pi | 2017 | Liver Research2017，1，2： | 3 |
| 2 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 3 | Gemcitabine-based combinations for inoperable pancreatic cancer:have we made real progress?A meta-analysis of 20 phase 3 trials显示文摘 | Bria E Milella M Gelibter A | 2007 | Cancer2007，110，3： | 1 |
| 4 | Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non - small - cell lung cancer 显示文摘 | Bria E Visca P Novelli F | 2008 | Eur J Surg Oncol2008，34，5： | 1 |
| 5 | CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors显示文摘 | Matteo Santoni Sergio Bracarda Massimo Nabissi Francesco Massari Alessandro Conti Emilio Bria Giampaolo Tortora Giorgio Santoni Stefano Cascinu Yi-Fang Ping | 2014 | BioMed Research International2014，，： | 1 |
| 6 | Is recurrent venous throm- boembolism after therapy reduced by low - molecular - weight heparin compared with oral anticoagulants 显示文摘 | Ferretti G Bria E Giannarelli D etal | 2006 | Chest2006，130，6： | 1 |
| 7 | First Line gefitinib (G) for advanced non small cell lung cancer (NSCLC) patients (pts) har- bouring sensitizing epidermal growth factor receptor mutations (EGFR M) Meta-analysis of randomized trials (RCT) explo- ring the magnitude of benefits over chemotherapy (CT) 显示文摘 | Ciannarelli D Bria E Milella M | 2010 | J Clin Oncol2010，，： | 1 |
| 8 | Ginkgo biloba and donepezil:a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study显示文摘 | Mazza M Capuano A Bria P | 2006 | Eur J Neurol2006，13，： | 1 |
| 9 | Weekly epirubicin and paclitaxel with anulyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study 显示文摘 | Nistic C Bria E Cuppone F | 2007 | Antieaneer Drugs2007，18，6： | 1 |
| 10 | Prevention of che- motherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: From guidelines to clinical prac- tice in solid tumors显示文摘 | Di Maio M Bria E Banna GL | 2013 | Anticancer Drugs2013，24，2： | 1 |
| 11 | Trastuzumab cardio toxicity:biological hypotheses and clinical open issues显示文摘 | Bria E Cuppone F Milella M | 2015 | Expert Opin Biol Ther2015，8，12： | 1 |
| 12 | Emerging pathways and future targets for the molecular therapy of pancreatic cancer显示文摘 | VACCARO V MELISI D BRIA E | 2011 | Expert Opin Ther Targets2011，15，10： | 1 |
| 13 | Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small- cell lung cancer 显示文摘 | Bria E Visca P Novelli F | 2008 | Eur J Surg Oncol2008，34，5： | 1 |
| 14 | Correlates of daytime sleepiness in patients with asthma 显示文摘 | Teodorescu M Consens FB Bria WF | 2006 | Sleep Med2006，7，： | 1 |
| 15 | Benefit of taxanes as adju- vant chemotherapy for early breast cancer: pooled analysis of 15 500 patients 显示文摘 | Bria E Nistico C Cuppone F | 2006 | Cancer2006，106，11： | 1 |
| 16 | Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?显示文摘 | Ferretti G Bria E Giannarelli D | 2006 | Chest2006，130，6： | 1 |
| 17 | Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis显示文摘 | Bria E Milclla M Cnpponc F | 2011 | Annals ofoncology2011，22，10： | 1 |
| 18 | EGFR molecular profiling in advanced NSCLC:a prospective phase Ⅱ study in molecularly/clinicallyselected patients pretreated with chemotherapy显示文摘 | Milella M Nuzzo C Bria E | | 0，，04： | 1 |
| 19 | Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials 显示文摘 | Bria E Milella M Gelibter A | 2007 | Cancer2007，110，3： | 1 |
| 20 | 4th - Generation Wireless Infrastructures: Scenarios and Research Challenges 显示文摘 | BRIA A GESSLER F QUESETH O | 2001 | IEEE Press on Communications2001，8，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员